As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.
15 Analysts have issued a Organon & Co. forecast:
15 Analysts have issued a Organon & Co. forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | 6,281 6,281 |
1%
1%
|
|
| Gross Profit | 3,534 3,534 |
5%
5%
|
|
| EBITDA | 1,678 1,678 |
6%
6%
|
|
| EBIT (Operating Income) EBIT | 1,359 1,359 |
2%
2%
|
|
| Net Profit | 700 700 |
30%
30%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Organon & Co. is a science based global pharmaceutical company that develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020 and is headquartered in Jersey City, NJ.
| Head office | United States |
| CEO | Kevin Ali |
| Employees | 10,000 |
| Founded | 2020 |
| Website | www.organon.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


